ArticlePatient preference and adherence2026
Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Health-related quality of life (HRQoL) and treatment satisfaction are critical endpoints in people living with HIV (PLWH) receiving antiretroviral therapy (ART). We aimed to analyze the HRQoL of PLWH receiving CAB+RPV LA and their experience with the healthcare they received. Methods: We conducted a prospective observational cohort study. We reviewed PLWH who initiated CAB+RPV LA and were followed for at least 15 months. Patient-Reported Outcomes (PROs) instruments were employed to measure health status (MOS-HIV: Physical Health Summary (PHS) and Mental Health Summary (MHS) scores) and ad hoc satisfaction questionnaire developed by the authors. Furthermore, patient experience with healthcare professionals (IEXPAC) was also evaluated. A subanalysis was conducted in an independent cohort of PLWH receiving oral ART. Results: In pooled analysis (n=104), patients reported high satisfaction after 15 months of LA therapy and maintained a good HRQoL; however, no statistically significant changes were detected following the switch from oral ART to CAB+RPV LA (PHS: 54±9 at baseline vs 53±10 at month 13; MHS: 52±10 vs 50±12; IEXPAC: 8.0±1.2 vs 7.5±1.5, respectively). The subanalysis of the oral ART group revealed no significant differences in MOS-HIV and IEXPAC questionnaires, compared to LA therapy. Conclusion: PLWH receiving CAB+RPV LA as an alternative to daily oral ART, demonstrate high satisfaction, maintained quality of life and positive relationships with healthcare professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.